The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT01610414




Registration number
NCT01610414
Ethics application status
Date submitted
31/05/2012
Date registered
4/06/2012
Date last updated
23/01/2018

Titles & IDs
Public title
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
Scientific title
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Secondary ID [1] 0 0
2012-000138-20
Secondary ID [2] 0 0
115523
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Herpes Zoster 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Herpes Zoster vaccine GSK1437173A
Other interventions - Placebo

Experimental: GSK1437173A Group - Subjects received 2 doses of the candidate HZ vaccine GSK 1437173A, administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.

Placebo Comparator: Placebo Group - Subjects received 2 doses of placebo (saline solution), administered intramuscularly (IM) in deltoid region of non-dominant arm, according to a 0, 1 Month schedule.


Other interventions: Herpes Zoster vaccine GSK1437173A
2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm

Other interventions: Placebo
2 doses administered IM in deltoid region of non-dominant arm

Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Subjects With Confirmed Herpes Zoster (HZ) Episode - A suspected case of HZ was defined as (1) a new rash characteristic of HZ (e.g., unilateral, dermatomal and accompanied by pain broadly defined to include allodynia, pruritus or other sensations), or a vesicular rash suggestive of VZV infection regardless of the distribution, and no alternative diagnosis; or (2) a clinical presentation (symptoms and/or signs) and specific laboratory findings* suggestive of VZV infection in the absence of characteristic HZ or VZV rash.
A suspected case of HZ was confirmed either: by Polymerase Chain Reaction (PCR) or by the HZ Ascertainment Committee (HZAC), consisting of physicians with HZ expertise.
Timepoint [1] 0 0
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Secondary outcome [1] 0 0
Duration of 'Worst' HZ-associated Pain - Duration of HZ-associated pain rated as 3 or greater on the 'worst pain' Zoster Brief Pain Inventory (ZBPI) question, following the onset of a confirmed HZ rash over the entire pain reporting period in subjects with confirmed HZ; presented as T (day) [=the sum of follow-up period (for subjects without severe worst pain T is 1, for subjects with severe worst pain T is the duration of severe worst pain) expressed in days].
Timepoint [1] 0 0
From Month 0 until study end (4 years approximately), from the onset of a confirmed HZ rash over the entire pain reporting period
Secondary outcome [2] 0 0
Number of Subjects With Confirmed HZ-associated Complications - This analysis excluded complications that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Timepoint [2] 0 0
From Month 0 until the cut-off date for final analysis (median follow-up was of 21 months)
Secondary outcome [3] 0 0
Number of Subjects With Postherpetic Neuralgia (PHN) - This analysis excluded PHN episodes that were linked to a confirmed HZ case that occurred after the start of the relapse treatment.
Timepoint [3] 0 0
From Month 0 until study end (21 months median follow-up)
Secondary outcome [4] 0 0
Antigen-glycoprotein E (gE) Antibody Concentrations in a Sub-cohort of Subjects - Anti-gE antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA), presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL). The seropositivity cut-off value was greater than or equal to (=) 97 mIU/mL.
Timepoint [4] 0 0
At Months 0, 1, 2, 13 and 25
Secondary outcome [5] 0 0
Number of Subjects With Any and Grade 3 Solicited Local Symptoms - Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Timepoint [5] 0 0
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary outcome [6] 0 0
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms - Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary/tympanic temperature equal to or above 37.5 degrees Celsius (°C) or rectal temperature equal to or above 38.0 °C]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
Timepoint [6] 0 0
During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Secondary outcome [7] 0 0
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) - An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Timepoint [7] 0 0
During the 30-day (Days 0-29) post-vaccination period
Secondary outcome [8] 0 0
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs) - Potential immune-mediated diseases (pIMDs) are a subset of AEs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology.
Timepoint [8] 0 0
From Month 0 up to 365 days post last vaccination
Secondary outcome [9] 0 0
Number of Subjects With Any Relapse - Relapse was defined as the occurrence of the underlying malignancy or disease for which the HCT was undertaken.
Timepoint [9] 0 0
From Month 0 until study end (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Secondary outcome [10] 0 0
Number of Subjects With Any Serious Adverse Events (SAEs) and Related SAEs to GSK Study Vaccine/Placebo - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This enpoint also presents SAES related to the GSK study vaccine/placebo.
Timepoint [10] 0 0
From Month 0 until 365 days post last vaccination (approximate median of 29 months follow-up - minimum 1 year and maximum 4 years)
Secondary outcome [11] 0 0
Number of Subjects With Fatal SAEs and SAEs Related to Study Participation or to a GSK Concomitant Medication or Vaccination - Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study subject. This endpoint presents fatal SAEs and SAEs related to study participation or to a concurrent GSK medication/vaccine.
Timepoint [11] 0 0
From the Pre-vaccination visit (Up to 110 days prior Month 0) until study end (approximate median of 29 months follow-up minimum 1 year and maximum 4 years)

Eligibility
Key inclusion criteria
Study entry (enrollment) occurs at the Pre-vaccination visit.

- Subjects who the investigator believes can and will comply with the requirements of
the protocol.

- Written informed consent obtained from the subject.

- A male or female aged 18 years or older at the time of study entry.

- Has undergone or will undergo autologous HCT within 50-70 days prior to the first
vaccination with the study vaccine/placebo, and there are no plans for additional
HCTs.

- Female subjects of non-childbearing potential may be enrolled in the study. For this
study population, non-childbearing potential is defined as current tubal ligation,
hysterectomy, ovariectomy or post-menopause.

OR Female subjects of childbearing potential may be enrolled in the study, if the subject
has practiced adequate contraception for 30 days prior to vaccination with the study
vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has
agreed to continue adequate contraception during the entire treatment period and for 12
months after completion of the vaccination series (i.e., until Month 13).
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Use of any investigational or non-registered product other than the study vaccine
within 30 days preceding the first dose of study vaccine/placebo, or planned use
during the study period. However, the investigational use of a registered or
non-registered product to treat the subject's underlying disease for which the HCT was
undertaken, or a complication of the underlying disease, is allowed.

- Previous vaccination against HZ or varicella within the 12 months preceding the first
dose of study vaccine/placebo.

- Planned administration during the study of a HZ vaccine other than the study vaccine.

- Occurrence of a varicella or HZ episode by clinical history within the 12 months
preceding the first dose of study vaccine/placebo.

- History of allergic disease or reactions likely to be exacerbated by any component of
the vaccine or study material and equipment.

- Prophylactic antiviral therapy with activity against Varicella Zoster Virus (VZV)
expected to last more than 6 months after transplantation.

- Administration and/or planned administration of a vaccine not foreseen by the study
protocol between HCT and 30 days after the last dose of study vaccine/placebo.
However, licensed non-replicating vaccines may be administered up to 8 days prior to
dose 1and/or 2, and/or at least 14 days after any dose of study vaccine/placebo.

- HIV infection by clinical history.

- Pregnant or lactating female.

- Female planning to become pregnant or planning to discontinue contraceptive
precautions (if of childbearing potential) before Month 13 (i.e., one year after the
last dose of study vaccine/placebo).

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,TAS,VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Darlinghurst
Recruitment hospital [2] 0 0
GSK Investigational Site - Waratah
Recruitment hospital [3] 0 0
GSK Investigational Site - Westmead
Recruitment hospital [4] 0 0
GSK Investigational Site - Woodville
Recruitment hospital [5] 0 0
GSK Investigational Site - Hobart
Recruitment hospital [6] 0 0
GSK Investigational Site - Box Hill
Recruitment hospital [7] 0 0
GSK Investigational Site - East Melbourne
Recruitment hospital [8] 0 0
GSK Investigational Site - Heidelberg
Recruitment hospital [9] 0 0
GSK Investigational Site - Parkville
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2298 - Waratah
Recruitment postcode(s) [3] 0 0
2145 - Westmead
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
7000 - Hobart
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
3002 - East Melbourne
Recruitment postcode(s) [8] 0 0
3084 - Heidelberg
Recruitment postcode(s) [9] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Massachusetts
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
United States of America
State/province [15] 0 0
Wisconsin
Country [16] 0 0
Belgium
State/province [16] 0 0
Antwerpen
Country [17] 0 0
Belgium
State/province [17] 0 0
Brugge
Country [18] 0 0
Belgium
State/province [18] 0 0
Bruxelles
Country [19] 0 0
Belgium
State/province [19] 0 0
Gent
Country [20] 0 0
Belgium
State/province [20] 0 0
Hasselt
Country [21] 0 0
Belgium
State/province [21] 0 0
Jette
Country [22] 0 0
Belgium
State/province [22] 0 0
Leuven
Country [23] 0 0
Belgium
State/province [23] 0 0
Liege
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
New Brunswick
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Canada
State/province [29] 0 0
Saskatchewan
Country [30] 0 0
Czechia
State/province [30] 0 0
Hradec Kralove
Country [31] 0 0
Czechia
State/province [31] 0 0
Olomouc
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha 10
Country [33] 0 0
Czechia
State/province [33] 0 0
Praha 2
Country [34] 0 0
Estonia
State/province [34] 0 0
Tallinn
Country [35] 0 0
Finland
State/province [35] 0 0
Helsinki
Country [36] 0 0
Finland
State/province [36] 0 0
Tampere
Country [37] 0 0
Finland
State/province [37] 0 0
Turku
Country [38] 0 0
France
State/province [38] 0 0
Clermont-Ferrand Cedex 1
Country [39] 0 0
France
State/province [39] 0 0
Créteil cedex
Country [40] 0 0
France
State/province [40] 0 0
Grenoble cedex 9
Country [41] 0 0
France
State/province [41] 0 0
Marseille cedex 9
Country [42] 0 0
France
State/province [42] 0 0
Montpellier cedex 5
Country [43] 0 0
France
State/province [43] 0 0
Pessac cedex
Country [44] 0 0
France
State/province [44] 0 0
Rouen cedex 1
Country [45] 0 0
Germany
State/province [45] 0 0
Baden-Wuerttemberg
Country [46] 0 0
Germany
State/province [46] 0 0
Bayern
Country [47] 0 0
Germany
State/province [47] 0 0
Nordrhein-Westfalen
Country [48] 0 0
Germany
State/province [48] 0 0
Schleswig-Holstein
Country [49] 0 0
Germany
State/province [49] 0 0
Berlin
Country [50] 0 0
Greece
State/province [50] 0 0
Athens
Country [51] 0 0
Greece
State/province [51] 0 0
Thessaloniki
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Hong Kong
Country [53] 0 0
Hong Kong
State/province [53] 0 0
Tuen Mun
Country [54] 0 0
Israel
State/province [54] 0 0
Hafia
Country [55] 0 0
Israel
State/province [55] 0 0
Jerusalem
Country [56] 0 0
Italy
State/province [56] 0 0
Emilia-Romagna
Country [57] 0 0
Italy
State/province [57] 0 0
Friuli-Venezia-Giulia
Country [58] 0 0
Italy
State/province [58] 0 0
Lombardia
Country [59] 0 0
Italy
State/province [59] 0 0
Piemonte
Country [60] 0 0
Japan
State/province [60] 0 0
Fukuoka
Country [61] 0 0
Japan
State/province [61] 0 0
Gunma
Country [62] 0 0
Japan
State/province [62] 0 0
Hiroshima
Country [63] 0 0
Japan
State/province [63] 0 0
Hyogo
Country [64] 0 0
Japan
State/province [64] 0 0
Kumamoto
Country [65] 0 0
Japan
State/province [65] 0 0
Nagasaki
Country [66] 0 0
Japan
State/province [66] 0 0
Niigata
Country [67] 0 0
Japan
State/province [67] 0 0
Okayama
Country [68] 0 0
Japan
State/province [68] 0 0
Shizuoka
Country [69] 0 0
Japan
State/province [69] 0 0
Tokyo
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Daegu
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Incheon
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Jellanamdo
Country [73] 0 0
Korea, Republic of
State/province [73] 0 0
Jeonju
Country [74] 0 0
Korea, Republic of
State/province [74] 0 0
Kyunggi-do
Country [75] 0 0
Korea, Republic of
State/province [75] 0 0
Seoul
Country [76] 0 0
Malaysia
State/province [76] 0 0
Kuala Lumpur
Country [77] 0 0
Malaysia
State/province [77] 0 0
Selangor
Country [78] 0 0
Netherlands
State/province [78] 0 0
Leiden
Country [79] 0 0
New Zealand
State/province [79] 0 0
Christchurch
Country [80] 0 0
New Zealand
State/province [80] 0 0
Grafton
Country [81] 0 0
New Zealand
State/province [81] 0 0
Wellington
Country [82] 0 0
Panama
State/province [82] 0 0
Panama
Country [83] 0 0
Poland
State/province [83] 0 0
Gliwice
Country [84] 0 0
Poland
State/province [84] 0 0
Krakow
Country [85] 0 0
Poland
State/province [85] 0 0
Warszawa
Country [86] 0 0
Romania
State/province [86] 0 0
Bucharest
Country [87] 0 0
Romania
State/province [87] 0 0
Tirgu Mures
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Moscow
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Novosibirsk
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Petrozavodsk
Country [91] 0 0
Russian Federation
State/province [91] 0 0
St'Petersburg
Country [92] 0 0
Russian Federation
State/province [92] 0 0
St.-Petersburg
Country [93] 0 0
Russian Federation
State/province [93] 0 0
St.Petersburg
Country [94] 0 0
South Africa
State/province [94] 0 0
Gauteng
Country [95] 0 0
South Africa
State/province [95] 0 0
Western Province
Country [96] 0 0
South Africa
State/province [96] 0 0
Groenkloof
Country [97] 0 0
South Africa
State/province [97] 0 0
Moreleta Park, Pretoria
Country [98] 0 0
Spain
State/province [98] 0 0
Badalona/Barcelona
Country [99] 0 0
Spain
State/province [99] 0 0
Barcelona
Country [100] 0 0
Spain
State/province [100] 0 0
La Coruña
Country [101] 0 0
Spain
State/province [101] 0 0
León
Country [102] 0 0
Spain
State/province [102] 0 0
Madrid
Country [103] 0 0
Spain
State/province [103] 0 0
Majadahonda (Madrid)
Country [104] 0 0
Spain
State/province [104] 0 0
Malaga
Country [105] 0 0
Spain
State/province [105] 0 0
Murcia (El Palmar)
Country [106] 0 0
Spain
State/province [106] 0 0
Murcia
Country [107] 0 0
Spain
State/province [107] 0 0
Oviedo
Country [108] 0 0
Spain
State/province [108] 0 0
Pozuelo De Alarcón/Madrid
Country [109] 0 0
Spain
State/province [109] 0 0
San Sebastián
Country [110] 0 0
Spain
State/province [110] 0 0
Santander
Country [111] 0 0
Spain
State/province [111] 0 0
Valencia
Country [112] 0 0
Taiwan
State/province [112] 0 0
Kaohsiung
Country [113] 0 0
Taiwan
State/province [113] 0 0
Taichung
Country [114] 0 0
Taiwan
State/province [114] 0 0
Taoyuan Hsien
Country [115] 0 0
Turkey
State/province [115] 0 0
Ankara
Country [116] 0 0
Turkey
State/province [116] 0 0
Istanbul
Country [117] 0 0
Turkey
State/province [117] 0 0
Izmir
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Lanarkshire
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Wiltshire
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Bournemouth
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Cottingham
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Headington, Oxford
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Leeds
Country [124] 0 0
United Kingdom
State/province [124] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A
in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant
recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy
(VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in
reducing the risk of developing HZ in this population.
Trial website
https://clinicaltrials.gov/show/NCT01610414
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications